Abstract
Osteonecrosis of the jaws (ONJ) can be a serious complication of radiation and anti-resorptive therapies. At present, patients due to undergo radiotherapy are required to have a dental assessment to treat current or anticipated dental disease prior to commencing treatment. However no agreed guidelines are in place for those due to start anti-resorptive therapy for cancer. More patients are now being treated with various drug therapies and new combinations of drugs with unknown long-term effects, with many patients now surviving their disease for longer periods of time. It is important to increase awareness among patients and dental professionals of the possibility of them developing medication-related osteonecrosis of the jaw (MRONJ) and to put in place effective preventative measures to help to stop such complications developing.
Case Report
A 52-year-old patient with a complex medical history, including metastatic breast cancer, presented with generalised oral pain and tooth mobility (see Figure 1). The patient developed extensive stage III MRONJ following concurrent use of multiple anti-resorptive therapies for treatment of secondary bone disease. Dental treatment consisted of provision of antibiotics, hydrogen peroxide and chlorhexidine mouthwashes prior to the extraction of symptomatic teeth and the multiple bony sequestra.
Conclusion
Once established, stage III MRONJ can be challenging to manage for both the dental team and for the patient. This case demonstrates the importance of a comprehensive dental examination and need for preventative dental treatment prior to starting anti-resorptive therapy in order to prevent such instances.
Keywords
Get full access to this article
View all access options for this article.